Divestitures, New Offerings, Strategic Partnerships and Management Appointments to Deliver Quality Patient Care - Research

      Divestitures, New Offerings, Strategic Partnerships and Management
   Appointments to Deliver Quality Patient Care - Research Report on Quest
              Diagnostics, Covance, Alere, PAREXEL, and TearLab

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, October 4, 2013

NEW YORK, October 4, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Quest
Diagnostics Inc. (NYSE: DGX), Covance Inc. (NYSE: CVD), Alere Inc. (NYSE:
ALR), PAREXEL International Corporation (NASDAQ: PRXL), and TearLab
Corporation (NASDAQ: TEAR). Today's readers may access these reports free of
charge - including full price targets, industry analysis and analyst ratings -
via the links below.

Quest Diagnostics Inc.Research Report

On October 1, 2013, Quest Diagnostics Inc. (Quest Diagnostics) announced that
it has completed the sale of its Enterix colorectal cancer screening test
business to Clinical Genomics Technologies Pty Ltd. on September 30, 2013.
Based on a preliminary analysis, the Company expects to record a loss of
approximately $25 million after tax, or $0.17 per share, for Q3 2013 on sale
of the Enterix business. The Full Research Report on Quest Diagnostics Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/05ba_DGX]

Covance Inc.Research Report

On September 25, 2013, Covance Inc. (Covance) announced the launch of external
laboratory management services, a new offering that provides biopharmaceutical
companies with a comprehensive management solution for external laboratory
testing associated with clinical trials. These services include laboratory
selection and qualification, auditing, vendor management, contracting and data
cleaning. Gary Paul, Global Director of Quality Assurance for Covance Central
Laboratory Services said, "As the pioneer of the central laboratory model,
this new offering further establishes Covance's position as a leader and
innovator in clinical trials testing and sets a new industry standard for the
management of data quality." The Full Research Report on Covance Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/5691_CVD]

Alere Inc.Research Report

On September 23, 2013, Alere Inc. (Alere) announced that it has partnered with
Malaria No More on its Power of One campaign. The campaign will raise funds to
deliver life-saving tests and treatment to children in Africa. Under this
campaign, Malaria No More, a non-profit organization to end malaria deaths,
will collaborate with Alere on the initiative to fight against Malaria. "As
the world's leading provider of rapid diagnostic tests for malaria, Alere is
deeply committed to working with partners such as Malaria No More to prevent
deaths from this devastating disease, one that particularly strikes young
children," said Avi Pelossof, Global President of Infectious Disease at Alere.
"We encourage people to support the Power of One campaign and help end malaria
deaths in sub-Saharan Africa." The Full Research Report on Alere Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/5da1_ALR]

PAREXEL International CorporationResearch Report

On September 24, 2013, PAREXEL International Corp. (Parexel) announced the
schedule of the release of its Q1 FY 2014 financial results. The Company has
set the earnings release date of October 29, 2013, Tuesday, after the close of
the stock market. Parexel will also host a conference call and live webcast at
10:00 a.m. ET on October 30, 2013 to discuss the results. The Full Research
Report on PAREXEL International Corporation - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.analystscorner.com/r/full_research_report/067b_PRXL]

TearLab CorporationResearch Report

On October 1, 2013, TearLab Corp. (TearLab) announced that Seph Jensen has
been appointed as the Company's President and Chief Operating Officer. The
Company reported that Mr. Jensen has a strong track record in sales and
marketing, operations and general management success in the ophthalmic
industry. "Seph is a seasoned leader with a strong track record of delivering
operational excellence and profitable growth," commented TearLab's Chief
Executive Officer, Elias Vamvakas. "I have tremendous confidence in his
ability to help us build our sales infrastructure and sharpen our execution.
Most importantly, he is exceptionally qualified to help us continue to build a
unique and powerful partnership within the eye care community." The Full
Research Report on TearLab Corporation - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.analystscorner.com/r/full_research_report/58d3_TEAR]

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

www.AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas: +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.